Glofitamab ELISA Kit

Glofitamab (RG6026) is a novel T-cell-engaging, bispecific antibody that binds bivalently to CD20 on B cells, and monovalently to CD3 on T cells. In study NP30179 (NCT03075696), an ongoing Phase I/II dose-escalation and expansion study, glofitamab fixed-dosing (0.6-25mg) with obinutuzumab pre-treatment (Gpt) achieved high, durable CRs with manageable safety in pts with heavily pre-treated R/R NHL (Dickinson et al. EHA 2020) . Step-up dosing (SUD) of glofitamab, in addition to Gpt, allowed dose-escalation up to the highest planned dose of 30mg to maximize efficacy, while mitigating cytokine release syndrome (CRS; [Hutchings et al. J Clin Oncol 2021]) . We present updated duration of response (DoR) data from the glofitamab monotherapy fixed-dosing and SUD cohorts of study NP30179 in pts with R/R NHL.

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.